Baxter Faces Expanding Securities Suits Over Novum Infusion Pump Defects
Plaintiff firms set a December 15 deadline for investors to seek lead-plaintiff status following complaints that Baxter hid safety failures tied to its Novum LVP.
Overview
- Lowey Dannenberg reports a complaint filed on October 16, 2025, alleging Baxter misled investors about Novum LVP safety, rollout, customer feedback, and sales prospects.
- Bernstein Liebhard announces a case for investors who bought Baxter shares between February 23, 2022 and July 30, 2025.
- Bronstein, Gewirtz & Grossman promotes a separate filing defining a class period from February 23, 2023 to July 30, 2025.
- The complaints assert systemic Novum LVP defects that caused underinfusion, overinfusion, and non-delivery, with reports of injuries and deaths and inadequate customer alerts.
- Filings state Baxter’s stock fell when investors learned of the alleged safety issues and related risks to the product’s commercialization.